Navigation Links
Micromet Added to Russell 3000 Index
Date:6/29/2009

Nycomed. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human antibody MT228 for the treatment of melanoma.

Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. A BiTE antibody targeting CEA for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, Micromet has entered into an option, collaboration and license agreement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do n
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
2. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
3. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
4. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
5. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
6. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
7. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
8. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
9. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
10. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
11. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... -- The 12th Cold Chain GDP & Temperature Management ... at the John B. Hynes Convention Center. The remarkable ... for a weeklong conference attracting industry executives from around ... to cover the industry,s most pressing topics, with an ... range products, GDP compliance requirements and supply chain integrity. ...
(Date:9/29/2014)...  Perrigo Company plc (NYSE: PRGO ... a portfolio of preclinical research assets, which it ... Corporation plc, to drug discovery and development company, ... will receive an upfront payment in addition to ... future sales derived from the portfolio. ...
(Date:9/29/2014)... Sept. 29, 2014  Xcenda, the strategic consulting ... pharmaceutical sourcing and distribution service companies, recently conducted ... This research was analyzed in an economic model ... with an increase in life years and a ... population-level coffee consumption across the United ...
(Date:9/29/2014)... Westbridge Agricultural Products announced today ... highly effective new tool for organic growers. SUPPRESS™ ... contact herbicide for post-emergent, non-selective weed control for ... The formulation is an emulsifiable concentrate that has ... (OMRI) for use in organic food production. , ...
Breaking Biology Technology:12th Cold Chain GDP & Temperature Management Logistics Global Forum Officially Kicks Off in Boston 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 3Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 4Coffee Consumption May Increase Survival and Reduce Healthcare Costs 2Coffee Consumption May Increase Survival and Reduce Healthcare Costs 3Westbridge Receives EPA Approval for Its New SUPPRESS™ Herbicide EC 2
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ... research group at The Institute of Cancer Research, ... combination treatment schedules,of reovirus and radiation in human ... The paper, entitled "Enhanced In vitro and In ...
... environment and holding it indefinitely in molecular-sized containers has been ... say it represents a novel method of gas storage that ... safely and efficiently. , This is a proof of concept ... just improving on a method that already exists, said U ...
... the economy is not,only heading towards a recession but ... during January. However, biotech held steady,with the Burrill Biotech ... posted a January loss of 9.9%, and the Dow, ... ride out extremely volatile capital,markets with less damage because ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy 2Rounding up gases, nano-style 2January Market Jitters Fails to Derail Biotech 2January Market Jitters Fails to Derail Biotech 3January Market Jitters Fails to Derail Biotech 4
(Date:9/29/2014)... Advocacy Awards will honor ... medical progress to improve the health and economic ... place on Wednesday, March 11, 2015, at the ... The 2015 Advocacy Award winners are ABC,s "Good ... of the Milken Institute and FasterCures; Dr. Kenneth ...
(Date:9/29/2014)... Energy Joint Genome Institute (DOE JGI), a DOE ... 32 new projects have been selected for the ... lakes to Caribbean waters, and from plant root ... in forested watersheds, the CSP 2015 projects portfolio ... be extracted. , "These projects catalyze JGI,s ...
(Date:9/29/2014)... WASHINGTON, Sept. 29, 2014 Oktoberfest is ... nothing worse than reaching for a cold ... your beer,s been skunked: chemicals have reacted ... bitter taste. This week, Reactions explains why ... do to keep your brews from going ...
Breaking Biology News(10 mins):Research!America to honor leaders in medical and health research advocacy 2Research!America to honor leaders in medical and health research advocacy 3Research!America to honor leaders in medical and health research advocacy 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9
... Biochemistry and Molecular Biology (ASBMB) has announced that ... the Cleveland Clinic,s Lerner Research Institute and emeritus ... is the recipient of the society,s 2011 Herbert ... The lectureship recognizes outstanding lifetime scientific ...
... Researchers at the University of Oklahoma ... new type of gene therapy to prevent blindness caused by retinitis ... this debilitating disease. ... Federation of American Societies for Experimental Biology (FASEB). The research, ...
... This release is available in German . ... researchers in Germany, the Deutsche Forschungsgemeinschaft (DFG, German Research ... decision was made by the DFG,s relevant Grants Committee ... doctoral researchers to complete their training at a highly ...
Cached Biology News:Dr. George Stark receives 2011 Herbert Tabor/Journal of Biological Chemistry Lectureship from ASBMB 2OU researchers find way to prevent blindness in research model for retinitis pigmentosa 2DFG establishes 12 new research training groups 2DFG establishes 12 new research training groups 3DFG establishes 12 new research training groups 4DFG establishes 12 new research training groups 5DFG establishes 12 new research training groups 6
...
Anti-Tissue Trans-glutaminase (IgA) EIA Sample Size: 10 l...
... Methylation-specific PCR (MSP) is a ... abnormal gene methylation utilizing small amounts ... an initial bisulfite reaction to modify ... with specific primers designed to distinguish ...
... The iEMS Incubator/Shaker HT ... Thus, the iEMS Incubator/Shaker HT ... as DNA hybridization and primer ... is available as a one-cabinet ...
Biology Products: